Premium
Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a ‘pre‐induction’ course for rapid tumour reduction: preliminary results on 66 patients
Author(s) -
Simon Daenen,
GW van Imhoff,
Eva van den Berg,
PJ de Kam,
Hanny Haaxma-Reiche,
Edo Vellenga,
Jw Smit,
RM Halie
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.00559.x
Subject(s) - medicine , etoposide , cytarabine , chemotherapy , induction chemotherapy , surgery , acute lymphocytic leukemia , gastroenterology , white blood cell , toxicity , bone marrow , leukemia , lymphoblastic leukemia
Sixty‐six consecutive adult patients with acute lymphoblastic leukaemia (ALL) were treated with intensified chemotherapy which included a ‘pre‐induction’ course of cytarabine (AraC) and etoposide (VP16) when the white blood cell count (WBC) was ≥30 × 10 9 /l (18 patients), and maintenance chemotherapy with regular intensifications for a total treatment duration of 3 years. Patients with a mediastinal mass (17) received consolidation courses with intermediate‐dose AraC and VP16 followed by mediastinal irradiation. 11 patients underwent allogeneic bone marrow transplantation in first complete remission (CR). 58 patients (87.9%, CI 77.5–94.6) attained CR; with a median follow‐up of 7 years, 35 of them (60.3%, CI 46.6–73.0) remain in CR. Toxicity was mild, although three patients died during remission induction, including two who were over 70 years of age. 23 patients (39.7%, CI 27.1–53.4) relapsed, seven of them primarily in the central nervous system (CNS), necessitating intensification of CNS‐directed therapy. Only one of 13 patients with WBC 30–100 × 10 9 /l, but eight of nine with WBC >100 × 10 9 /l, relapsed. The survival of older patients in CR did not differ from younger patients. The outcome of ALL in adult patients could thus be improved by slight intensification of treatment whilst keeping the toxicity within acceptable limits. ‘Pre‐induction’ with AraC and VP16 might improve the prognosis, especially in patients with WBC <100 × 10 9 /l. Patients with WBC >100 × 10 9 /l, however, almost always relapse, and the intensified chemotherapy might not be tolerated well by patients over 70 years of age.